Table 3.

Multivariate analysis of locoregional recurrence for propensity score-matched patients with breast cancer receiving total mastectomy under PB-RA with propofol or INHA-GA without propofol.

		LRR
		aHR*	(95% CI)	p-value
Anesthesia	INHA-GA	ref		0.0365
	Propofol	0.52	(0.28–0.96)
Age (years)	20–49	ref		0.9111
	50+	0.97	(0.55–1.72)
Diagnosis year	2009–2013	ref		0.2513
	2014–2018	1.13	(0.90–3.75)
Menopausal status	Premenopausal	Ref		0.7081
	Postmenopausal	0.81	(0.71–1.30)
CCI scores	0	ref		0.1309
	1	1.04	(0.80–1.06)
	2+	1.07	(0.76–2.49)
Differentiation	I	ref		0.0099
	II	1.16	(1.04–2.08)
	III	1.28	(1.07–2.12)
AJCC clinical stage	I	ref		0.0012
	II	3.71	(1.82–7.59)
	III	4.67	(1.65–13.18)
pT	pT1	ref		0.0260
	pT2	1.09	(1.02–1.21)
	pT3–4	1.17	(1.03–2.16)
pN	pN0	ref		0.0022
	pN1	1.10	(1.03–1.33)
	pN2–3	1.22	(1.06–2.41)
Nodal surgery	ALND	ref		0.3066
	SLNB	1.55	(0.72–3.36)
ASA	I	ref		0.2221
	II	1.16	(0.57–2.38)
	III-IV	1.89	(0.90–3.96)
Adjuvant chemotherapy	Yes	1.26	(0.71–2.25)	0.4343
Adjuvant RT	Yes	0.88	(0.64–0.94)	0.0413
HR	Positive	0.88	(0.68–3.28)	0.2252
HER2	Positive	1.64	(0.89–3.02)	0.1103
Hospital level	Academic centers	ref		0.1078
	Nonacademic	0.56	(0.28–1.13)

PB-RA, paravertebral block-regional anesthesia; GA, general anesthesia; INHA, inhalational; aHR, adjusted hazard ratios; CIs, confidence intervals; AJCC, American Joint Committee on Cancer; HR, Hormone Receptor; HER2, Human Epidermal Growth Factor Receptor-2; RT, radiotherapy; ASA, American Society of Anesthesiology; CCI, Charlson comorbidity index; T, tumor; N, nodal; pT, pathological tumor stage; pN, pathological nodal stage; ALND, axillary lymph node dissection; SNLB, sentinel lymph node biopsy; ref, reference group.

*All covariates mentioned in Table 2 were adjusted.